Vascular Biogenics Ltd (NASDAQ:VBLT)
| 0.1652 Delayed Data As of Feb 02 |  +0.0008 / +0.48%Today’s Change | 0.10 Today|||52-Week Range 2.20 | +37.67% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $10.4M |
Company Description
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
Contact Information
Vascular Biogenics Ltd. 8 HaSatat Street Modi’in Jerusalem 7178106 |
Employees
Shareholders
| Individual stakeholders | 8.79% |
| Other institutional | 4.79% |
| Mutual fund holders | 0.08% |
Top Executives
| Dror Harats | Chief Executive Officer & Director |
| Eyal Breitbart | Senior Vice President-Research & Operations |
| Erez Feige | Senior Vice President-Business Operations |
| Samuel I. Backenroth | Chief Financial Officer |
| Tami Rachmilewitz | Senior Vice President-Clinical Development |
